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Genetic epidemiology of diabetes
M. Alan Permutt,1 Jonathon Wasson,1 and Nancy Cox2
1Department of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, Missouri, USA.  
2Department of Human Genetics, The University of Chicago, Chicago, Illinois, USA.
Conventional genetic analysis focuses on the genes that account for specific phenotypes, while traditional epide-
miology is more concerned with the environmental causes and risk factors related to traits. Genetic epidemiology 
is an alliance of the 2 fields that focuses on both genetics, including allelic variants in different populations, and 
environment, in order to explain exactly how genes convey effects in different environmental contexts and to arrive 
at a more complete comprehension of the etiology of complex traits. In this review, we discuss the epidemiology 
of diabetes and the current understanding of the genetic bases of obesity and diabetes and provide suggestions for 
accelerated accumulation of clinically useful genetic information.
Definition of the problem
Diabetes is a metabolic condition in which the body fails to pro-
duce enough insulin. Type 1 diabetes (T1D) results from autoim-
mune destruction of insulin-producing β cells, which leaves the 
patient dependent on insulin injections for survival (1) T2D, for-
merly known as adult-onset diabetes, occurs when impaired insulin 
effectiveness (insulin resistance) is accompanied by the failure to 
produce sufficient β cell insulin. Patients can be placed on regimens 
to reduce weight or manage diet or treated with medication and, 
less often, insulin injections. This latter form of diabetes accounts 
for as much as 95% of cases. Gestational diabetes is another form of 
diabetes, defined as a state of glucose intolerance during pregnancy 
that usually subsides after delivery but has major implications for 
subsequent risk of T2D, as pregnancy serves as an “environmental” 
stressor that reveals a genetic predisposition. Other less common 
forms of diabetes include the rare, genetically determined disease 
maturity onset diabetes of the young (MODY), diabetes resulting 
from surgery, and other illnesses that constitute only 1–5% of cases. 
Based on plasma glucose measurements, 2 conditions have been 
identified with increased risk of the disease (2): (a) impaired glucose 
tolerance (IGT) is defined as hyperglycemia intermediate between 
normal and diabetic levels following a glucose load; (b) impaired 
fasting glucose (IFG), like IGT, is associated with increased cardio-
vascular disease (CVD) and future diabetes. Because complications 
of diabetes may develop years before overt disease, many consider 
the disease part of a cluster of CVD risk factors that include hyper-
tension, hyperinsulinemia, dyslipidemia, visceral obesity, hyperco-
agulability, and microalbuminuria. This collection of risk factors is 
also known as the metabolic syndrome (3, 4).
While insulin therapy can reverse many of the metabolic distur-
bances, and numerous improvements in management have been 
introduced (5), the disease has reached epidemic proportions. 
According to the WHO (6), it is likely to be one of the most sub-
stantial threats to human health in the 21st century.
Prevalence
The prevalence of diabetes in the United States has risen 40%, from 
4.9% in 1990 to 6.9% in 1999 (7). A breakdown of the prevalence of 
diabetes by state from 1990 through 2001 and of obesity by state 
from 1991 through 2003 is shown in Figure 1, A and B, respective-
ly (8, 9). The disease affects various groups differently, occurring 
10 times more commonly in those older than 65 years compared 
with those younger than 45 years. Minority racial groups including 
Hispanics, African Americans, and Native Americans are generally 
affected at a rate 2–4 times that for white individuals. The recent 
increased prevalence has also been noted in children and adoles-
cents, where T2D may now occur more commonly than T1D (10). 
The estimated lifetime risk of developing diabetes for individuals 
born in the United States in 2000 is 33% for males and 39% for 
females (7). It is highest among Hispanic females, at 53%. Diabetes 
is associated with large reductions in life expectancy, on the order 
of 11 years in males diagnosed at age 40. While an estimated 18.2 
million persons had diabetes in the United States in 2002 (11), dia-
betes worldwide has been estimated to affect 151 million persons, 
and that number projected to increase to 324 million by 2025 (2).
The medical burden of diabetes
The burden of diabetes is to a large extent the consequence of 
macrovascular and microvascular complications of the disease, 
which result in large increases in morbidity and mortality. For 
example, the prevalence of ischemic heart disease is 2–14 times 
the rate in age-matched nondiabetics (12). Diabetic retinopathy 
is the chief cause of blindness in the US. In 2000, diabetic renal 
disease accounted for 40% of new cases of end-stage renal disease, 
and diabetics are the largest group receiving dialysis (more than 
50% of all cases) and renal transplants (approximately 25%). Lower 
extremity disease resulting from a combination of peripheral vas-
cular disease and neuropathy causes an increase in lower extremity 
amputations. While improved glycemic control has been shown 
to reduce the incidence of microvascular complications, episodes 
of severe symptomatic hypoglycemia were 3 times higher in those 
receiving intensive insulin management therapy (13). Along with 
experiencing physical and cognitive disabilities, adults with dia-
betes have an age-adjusted mortality rate estimated to be twice 
that of nondiabetics (12). Risk factors for CVD, including systolic 
hypertension, elevated cholesterol levels, and cigarette smoking, 
independently predict CVD mortality, and any 1 risk factor affects 
outcomes more in persons with diabetes (14).
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Although increase in diabetes prevalence occurs mostly in mid-
dle-aged and older adults, there is strong evidence of an increase 
in the prevalence of T2D in children (10). For example, in Japan 
the incidence in school children (6–15 years old) has doubled over 
a 20-year period, such that T2D is now more common than T1D 
(15). In the US, up to 45% of the newly diagnosed diabetics in the 
pediatric age group have T2D (10). This rise in diabetes rates in 
children reflects, at least in part, the growing prevalence of obesity 
in this age group (16).
Direct medical expenditures and lost productivity due to diabe-
tes were estimated to cost the US $132 billion in 2002 (17). The 
per capita expenditures were twice those for individuals without 
the disease. While the prevalence of diagnosed diabetes is less than 
5% of the population, almost $1 of every $5 spent on health care in 
the US is for patients with diabetes. As the prevalence of diabetes 
increases with age, and because of the increasing diabetes-prone 
populations, it has been estimated that the number of diagnosed 
cases will increase. Thus the projected total cost in 2002 dollars 
could be as high as $192 billion by 2020.
Etiology of the diabetes epidemic
The sudden increase in diabetes in the last few years is due not to 
genetic factors but rather to the increase in obesity. This phenom-
enon is currently being documented in Africa, where the incidence 
of diabetes is rising with urbanization. The incidence is also rising 
among Africans who have immigrated to the US (18, 19). Epide-
miological studies have regularly shown the relationship between 
diabetes and obesity, mediated in part by nutritional and lifestyle 
factors (20, 21). The most common measure of obesity, body mass 
index (BMI), combines measurements of height and weight. Peo-
ple with a BMI greater than 25 are said to be overweight, while 
those with a BMI greater than 30 are defined as obese (22). The 
Nurses Health Study showed that the risk for developing diabetes 
increased sharply for individuals observed as having a BMI greater 
than 23 for 16 years and was increased 20-fold for those with a 
BMI greater than 30 (18). In a recent study of measures of obesity 
and CVD risk factors in Australian adults, the prevalence of T2D 
rose from 5% in normal-weight to 16% in obese males; of hyperten-
sion, from 20% to 49%; and of dyslipidemia, from 18% to 61%, with 
even higher prevalence in females (23).
The molecular and physiological relationships between obesity 
and diabetes are not fully understood, and this subject is an area of 
intense investigation (see ref. 22 for review). The “thrifty genotype” 
hypothesis was proposed to account for a genetic advantage of 
accelerated fat deposition during times of restricted availability of 
calories, which leaves individuals faced with harmful consequenc-
es given the abundant food supply and reduced levels of physical 
activity in developed countries today (24). Noting an association 
between low birth weight and increased incidence of diabetes in 
later life, Hales and Barker have hypothesized that intrauterine mal-
nutrition result in reduced birth weight and to subsequent changes 
leading to disease in adults (25, 26). This phenomenon, also known 
as the “thrifty phenotype” hypothesis, proposes that fetal malnutri-
tion results in impaired pancreatic β cell development and insulin 
resistance. Offspring are subsequently more prone to diabetes and 
the metabolic syndrome when exposed to abundant nutrition later 
in life. In this regard, the increased prevalence of T2D in offspring 
of diabetic mothers may be a consequence of environmental fac-
tors operating on a genetic background, i.e., an altered intrauterine 
environment superimposed on a genetic predisposition in the fetus. 
While epidemiological studies have confirmed these observations, 
virtually nothing is known of their mechanisms, and this is an 
active area of investigation (27). If the relationship between obesity 
and diabetes could be understood, or obesity effectively prevented 
with treatment, then therapies directed at these mechanisms might 
curtail the increasing incidence of the disease.
The relationship between obesity and diabetes has been exten-
sively studied in inbred strains of mice (28). Mice from a single 
inbred strain fed a high-fat diet all became insulin resistant, yet 
only about half became both obese and diabetic. Interestingly, 10% 
became diabetic but resisted obesity, and 10% became obese but 
not diabetic. The mechanisms responsible are unlikely to be purely 
genetic, and the results are consistent with the hypothesis that epi-
genetic changes and stochastic factors contribute to the phenotyp-
ic diversity. More recently, ER stress was shown to be the etiology 
of obesity-induced insulin resistance and diabetes in experimental 
mouse models, and this mechanism promises to be a rewarding 
area of investigation in the near future (29). If the degree of ER 
stress varies among mice, then perhaps this could explain the phe-
notypic differences in mice that are genetically identical.
Figure 1
(A) Diabetes trends among adults in the US. *Includes gestational diabetes. Adapted from ref. 8. (B) Obesity trends among US adults. 
**BMI ≥ 30 (about 30 pounds overweight for a 5-ft 4-in. individual). Adapted from ref. 9.
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As it has long been noted that levels of FFAs are increased in 
obese individuals, their accumulation in skeletal muscle has been 
proposed to compete with circulating glucose resulting in hyper-
glycemia, hyperinsulinemia, and ultimately insulin resistance 
(30). Recently, using magnetic resonance spectroscopy in patients 
with obesity and/or T2D, Shulman et al. have shown a reduction 
in the rate of insulin-stimulated glucose metabolism secondary 
to reduced muscle glycogen synthesis, associated with a blunted 
increase in intramuscular glucose 6 phosphate relative to concen-
tration in insulin-resistant offspring of diabetic parents compared 
to control individuals (31, 32). Increased intracellular fatty acid 
metabolites were found to result in decreased insulin signaling 
and impaired glucose transport. Other factors contributing to the 
insulin resistance of obesity include the tendency to store fat in 
the abdominal region as opposed to the extremities and defects in 
adipocyte fatty acid metabolism and mitochondrial fatty acid oxi-
dation. While impaired mitochondrial activity in insulin-resistant 
offspring of patients with T2D has been observed (33), the genetic 
basis for reduced mitochondrial biogenesis has not been eluci-
dated. Reduced mitochondrial activity results in reduced energy 
expenditure, obesity, increased intramuscular fatty acid accumu-
lation, and insulin resistance and has therefore been incorporated 
into the thrifty gene hypothesis (32).
Heritability of diabetes
The recent increased prevalence of obesity and diabetes must be 
largely attributable to changes in nongenetic risk factors. Yet envi-
ronmental aspects must certainly accelerate the disease in those 
with genetic predisposition. There is a clear need to understand 
the genetic basis for the regulation of food intake, energy expen-
diture, and variations in energy balance in various individuals. 
In the long run, it may be more beneficial to develop treatments 
based on these genetic mechanisms than to rely on the use of will 
power to modify lifestyle. Moreover, different aspects of environ-
ment may be more critical in different subsets of individuals. We 
know from the natural history of diabetes complications that 
when patients are first diagnosed, there may already be marked 
progression of microvascular and macrovascular complications 
(34). The overwhelming majority of obese individuals have insulin 
resistance, yet only 5–10% develop pancreatic β cell failure and 
diabetes. Discovering the genetic risk factors for the disease will 
likely have many positive consequences.
The familial occurrences of both T1D and T2D have been long 
noted. A sibling’s risk of developing T1D (5–10%) is perhaps 12- to 
100-fold greater than the risk in the general population (0.1–0.4%) 
(35). Concordance in monozygotic (MZ) twins has been consis-
tently shown to be greater than that in dizygotic (DZ) twins (36). 
For T2D, the concordance among MZ twins has been observed to 
be 50–92%, higher than the 37% concordance in DZ twins (36). 
Thus while the relative risk to a sibling, a measure of the genetic 
contribution, is considerably greater for T1D than for T2D, the 
concordance and absolute risk are substantially greater for T2D, 
which perhaps underscores the importance of the environmental 
contribution to the latter (37).
Quantitative phenotypes related to glucose homeostasis are also 
known to be heritable (38). In families with an increased genetic 
susceptibility to T2D, heritability estimates for β cell function 
and features of the insulin resistance syndrome of 72% and 78%, 
respectively, were calculated (39). The heritability of other fea-
tures of the insulin resistance syndrome, including BMI, blood 
pressure, and serum lipid and insulin sensitivity levels, was also 
estimated to be high. Evidence for heritability of these metabol-
ic phenotypes was reported in studies of Pima Indians (40) and 
nondiabetic Japanese Americans (41); in the Insulin Resistance 
Atherosclerosis Study (IRAS) among family members of African 
American and Hispanic heritage (42); and in a study of the famil-
ial aggregation of the amount and distribution of subcutaneous 
fat and responses to exercise training in the HERITAGE Family 
Study (43). These studies strongly support the role of both genet-
ic and environmental factors in the etiology of diabetes and the 
insulin resistance syndrome.
The value of monogenic subtypes of diabetes
Recent reviews provide detailed appraisals of both linkage and asso-
ciation studies in diabetes (38, 44). We focus here on the patterns 
that have emerged in the search for genetic risk factors for diabetes. 
Linkage mapping, positional cloning, and candidate gene studies 
have been most successful in the forms of diabetes with the sim-
plest genetic models. Early studies characterizing diabetes resulting 
from mutations in insulin (INS) and insulin receptor (45) genes as well 
as the mitochondrial genome (46) provided important insights into 
glucose homeostasis, but it is the studies on MODY that provide 
the classic example of the successful application of genetics to dia-
betes (47, 48). Linkage mapping studies on MODY were quite suc-
cessful, and within a few years, a combination of positional cloning 
and studies of positional candidate genes led to the identification 
of glucokinase (GCK) and hepatocyte nuclear factors 4α and 1α (HNF4A 
and TCF1) as genes in which a single mutation could lead to the 
complex metabolic phenotype of diabetes (see ref. 49 for a recent 
review). GCK is the rate-limiting enzyme in glucose metabolism; 
HNF4A and TCF1 are transcription factors expressed in a variety of 
tissues, including the liver and pancreas where they work in a tran-
scription regulatory network to regulate the expression of genes 
involved in glucose transport and metabolism (49).
Once these genes had been implicated in MODY, a number of 
other transcription factors within the same regulatory network 
were also found to be MODY genes. As noted above, mutations 
in MODY genes, at the INS and INS receptor genes, or in the mito-
chondrial genome collectively account for only a small proportion 
of diabetes — about 1–5% (50). However, the monogenic forms of 
diabetes provide important insights into how we should be think-
ing about the genetic components of a phenotype as broad and 
metabolically complex as that of diabetes. The genes in which a 
single mutation is sufficient to generate this phenotype play an 
absolutely central role in glucose homeostasis (e.g., INS, the INS 
receptor, GCK) or are capable of affecting the regulation of many 
genes that act within this overall pathway (e.g., transcription fac-
tors). From these studies we learned that glucose homeostasis is 
a balance between insulin production, determined by β cell mass 
and/or function, and insulin action. Some of the genes that have 
been shown to affect these processes either in humans or experi-
mental animals are illustrated in Figure 2.
The general observations on the genes implicated in monogenic 
forms of diabetes fit well within the emerging theories for how bio-
logical networks might be expected to perform and suggest that 
a systematic application of network theory to the metabolic and 
regulatory pathways underlying glucose homeostasis may provide 
a fruitful avenue for prioritizing genes for future studies. Recent 
research suggests that a scale-free topology is a nearly universal fea-
ture of networks, whether we are considering air traffic patterns, 
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the Internet, or biological pathways in complex organisms (51–53). 
A network with scale-free topology is characterized by that there 
is a relatively small number of hubs that have substantially more 
connections than average, along with a much larger number of 
nodes that have a very limited number of other connections. Such 
networks can be very stable and robust but are most vulnerable at 
those hubs that have the most connections to other nodes. Using 
network theory with even the information we 
already have about the pathways implicated 
in glucose homeostasis, we could predict that 
genes/proteins located at hubs that are the 
most highly interconnected are those most 
vulnerable to degrading the overall system. 
Thus, genetic variation at hub genes may be 
more likely to lead to detectable perturba-
tions in glucose homeostasis. While we might 
use network theory to prioritize genes for 
study simply based on the relative connect-
edness of the genes at the hubs in the net-
works, it might also be useful to overlay such 
an analysis on existing information we have 
about potential genetic risk factors for dia-
betes via linkage mapping or linkage disequi-
librium mapping studies. A similar strategy 
was recently applied in studies of Alzheimer 
disease, with promising results (54).
Genetic studies on T1D
Genetic linkage studies of T1D and T2D have 
been quite variable, spanning the spectrum of 
results generally observed for disorders with 
complex inheritance. T1D is unique among 
complex disorders in the magnitude of the 
familial risk attributable to a single locus, 
HLA. While HLA was originally implicated 
through association studies as a candidate 
gene (55), the magnitude of the evidence for 
linkage at HLA in T1D is larger than has been 
observed for a linkage in any other complex 
disorder, although some other autoimmune 
disorders also have strong evidence for link-
age in the HLA region (56). Because of the 
major contribution of HLA to the familial 
risk of T1D, identification of the other genet-
ic risk factors may be more akin to identify-
ing modifier loci for monogenic disorders 
than identifying primary susceptibility loci 
for complex disorders. Indeed, the non-HLA 
genes that have been reproducibly character-
ized as T1D susceptibility loci have been iden-
tified largely through candidate gene studies. 
Evidence for linkage at the non-HLA loci implicated in T1D has 
been uneven at best. For example, the very common class I alleles 
at INS variable number of tandem repeats (VNTR) are significantly 
overtransmitted from parents heterozygous for this allele to off-
spring affected with T1D (57). There was no evidence for linkage 
of the INS region to T1D in 100 affected sibling pair (ASP) families 
(58) and only modest evidence in more than 200 families (59). In a 
Figure 2
Diabetes results from an imbalance between the 
insulin-producing capacity of the islet β cell and 
the requirement for insulin action in insulin target 
tissues such as liver, adipose tissue. and skeletal 
muscle. Some of the many genes that have been 
shown or could possibly contribute to the imbal-
ance are illustrated.
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large sample (767 families) including ASP families from both the 
US and the United Kingdom, there was significant evidence for 
linkage near INS (60). Similarly, initial evidence for linkage near 
CTLA4, another locus with support for affecting susceptibility to 
T1D through association studies, was detected in some individual 
samples, but little evidence for linkage in the region of CTLA4 was 
found in larger, combined samples (60). Finally, PTPN22, a locus 
recently implicated as a candidate gene in T1D (61), rheumatoid 
arthritis (62), and systemic lupus erythematosus (63), shows little 
evidence for linkage to T1D even in relatively large samples (60).
Genetic studies on T2D
The success of linkage mapping for T2D has been similar to that 
observed for other complex disorders, which has been, regrettably, 
quite limited. More than 25 genome-wide screens have been con-
ducted on samples from all over the world (for review, see ref. 44). 
Despite the number of studies, there are only a few regions with 
replicated evidence for linkage: 1q, 3q, 8p, 10q, 12q, and 20q. Even 
in these regions, however, evidence for linkage is far from universal 
(3–7 of the more than 25 studies show nominally significant evi-
dence for linkage), peaks are broad, and it is unlikely that all stud-
ies with linkage signal in a given region reflect the contribution of 
the same susceptibility genes.
Factors contributing to the complexity of analysis
Why has linkage mapping been relatively unsuccessful in localizing 
susceptibility genes for T1D and T2D in even relatively large, com-
bined data sets? The complexity of the underlying genetic model 
is clearly a contributing factor. We have almost certainly under-
estimated the number of different genetic risk factors for both 
disorders and overestimated the magnitude of effect that might 
be expected for any one of these loci, excepting, perhaps, HLA in 
T1D. It might be argued that the initial success with HLA in T1D, 
the first susceptibility gene successfully linked to a complex disor-
der, encouraged us to establish a series of unrealistic expectations 
for how genetic risk factors contribute to diabetes and other com-
plex disorders. Among the complexities of the genetic models for 
complex disorders that are likely to contribute to the difficulties 
in linkage mapping are gene-gene and gene-environment interac-
tions. Such interactions are difficult to accommodate in primary 
linkage mapping studies and yet are a requisite part of the defi-
nition of a complex trait. It is not clear whether these problems 
could be solved by increasing either the sample sizes for linkage 
studies or the number of phenotypes examined. In particular, the 
failure to adequately measure and account for nongenetic factors 
affecting risk of diabetes almost certainly has reduced our ability 
to successfully map genetic risk factors.
The diagnosis of diabetes has long been standardized and is both 
reliably and inexpensively achieved with a simple blood test. These 
factors contributed substantially to making diabetes the first com-
plex disorder to be widely studied using genetic tools. But the diag-
nosis of diabetes is designed to focus on the clinical consequences 
of elevated blood glucose levels rather than the underlying genetic 
liability to this very complex metabolic disease. The simple dichot-
omous diagnosis masks a tremendous amount of clinical hetero-
geneity, and it is likely that the genetic heterogeneity of diabetes 
is at least as great as the clinical heterogeneity. Thus, efforts to 
specify more genetically homogeneous samples according to clini-
cal characteristics might also be fruitful. For example, stratifying 
T1D families for linkage analyses according to antibody positiv-
ity, or patients with T2D by BMI, might lead to more consistent 
and reproducible results in linkage mapping studies. Additionally, 
analysis of quantitative traits that may be related to the primary 
dichotomous trait of T2D, such as insulin resistance, β cell mass 
and performance, BMI and other features of the metabolic syn-
drome, may lead to the identification of genes contributing to risk 
of T2D (64). Several such studies have been already been initiated 
(see ref. 65 for review), including a recent IRAS study of quantita-
tive traits in African American and Hispanic families (66), and the 
results point to promising genomic regions, though no causative 
genes have yet been identified. In this regard, use of animal mod-
els could help in gene identification, as syntenic regions are being 
evaluated in congenic strains in order to narrow regions conveying 
genetic risk for T2D, as, for example, in obese mice (67). We must 
also recognize, however, that the quantitative phenotypes that we 
now know how to measure easily are not necessarily the pheno-
types best able to characterize the genetic liability to T2D.
Emerging patterns and implications for study design
The patterns emerging from the linkage and association studies 
that have identified genetic risk factors for diabetes offer intrigu-
ing insights into the challenges we face in improving our study 
designs. Some of the factors are common but so low risk that 
they would be quite difficult to detect in linkage mapping stud-
ies. For example, the allele increasing risk of T2D at PPARG has 
a frequency of 0.85–0.95 in most of the world’s populations (68) 
and is associated with very modest increase in risk. Similarly, the 
class I alleles (or polymorphisms in linkage disequilibrium with 
them) increasing risk for T1D at the INS VNTR are found at very 
high frequency in populations of European and Asian descent 
(0.70–0.85), but they increase risk only modestly (69). There are 
rarer amino acid polymorphisms that have been reliably associated 
with diabetes. For example, the allele increasing risk of T2D at the 
T504A polymorphism at CAPN10 ranges in frequency from 0.04 to 
0.16 (70), and the allele increasing risk of T1D at the R620W poly-
morphism at PTPN22 ranges in frequency from 0.08 to 0.14 (69). 
But many of the polymorphisms associated with increased risk of 
diabetes identified to date are not amino acid polymorphisms. The 
variation at CTLA4 implicated in T1D appears to affect splicing 
(71), while variation at the INS VNTR (69), at CAPN10 (72), and 
at HNF4A (73, 74) (as discussed in more detail below) may affect 
gene expression. Linkage mapping, even with very large samples, 
will miss many of these risk factors. Similarly, genome-wide asso-
ciation mapping focused exclusively on common haplotypes will 
miss many of the rarer risk alleles. Strategies targeting known 
amino acid polymorphisms will miss rare, unknown susceptibility 
variants and may not detect the effects of the more common non-
coding sequence polymorphisms either. Until it becomes clearer 
whether there will be a predominant frequency spectrum or poly-
morphism type in the genetic variation affecting susceptibility to 
diabetes (whether type 1 or 2), it seems prudent to adopt strategies 
that enable detection of susceptibility alleles with a wide range of 
frequencies and effects. Some known genes associated or linked 
with diabetes are listed in Table 1 (61, 70, 73, 74, 90–117).
Sample size for low-risk genes associations
Identification of susceptibility alleles for T1D, outside the HLA 
locus, and T2D, whether through positional cloning or in the con-
text of studies on functional candidates, has been challenging. Ini-
tial positive results are usually only inconsistently replicated. For 
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example, conflicting results of different studies on the Pro12Ala 
polymorphism in the PPARG2 gene were resolved by analysis of 
large family and case control samples; and a meta-analysis of all 
published studies further demonstrated that this polymorphism 
does affect risk of T2D, but only to a small degree (68). Similarly 
the E23K polymorphism in the Kir6.2 subunit of the ATP-regulat-
ed potassium channel has been shown by meta-analysis to contrib-
ute a small but significant risk to the disease in the populations 
studied (75, 76). Except for HLA in T1D, the susceptibility alleles 
for T1D and T2D quite modestly affect risk of disease, which 
mandates the study of large sample sizes. This argues for large 
collaborative studies, wherein sample sizes will be on the order of 
thousands and replication will be conducted during the primary 
investigation rather than through the time-consuming process of 
publication of multiple individual studies.
Investigating potential regulatory regions  
of candidate genes through haplotype-tagged SNPs
While every nonsynonymous coding single nucleotide polymor-
phism (SNP) in candidate genes should be tested for possible 
contribution to disease susceptibility, 2 recent studies highlight 
the importance of conducting association studies with markers 
in potential regulatory regions. Earlier studies with SNPs in or 
near the coding region of HNF4A, a gene previously shown to be 
mutated in rare cases of MODY (77), had yielded no association 
with T2D (78). More recently, it was discovered that a second pro-
moter exists 40 kb upstream of the gene (79, 80) and that SNPs 
in the region of this second promoter and in other parts of the 
noncoding sequence of HNF4A were associated with T2D in Ash-
kenazi Jews (74) and in a sample in Finland (73). Results of follow-
up studies in other populations may provide some confirmation 
of the association between T2D and noncoding SNPs at HNF4A 
and its regulatory regions (81), but we should not be surprised if 
some studies in even large replication samples fail to observe asso-
ciations and should be equally prepared for the possibility that not 
all studies will identify the very same polymorphisms as showing 
association. The nature of regulatory variation virtually insures 
that effects attributable to one polymorphism might be attenu-
ated by effects of a second polymorphism — thus, the cumulative 
effects of regulatory variants may be poorly predicted by the mar-
ginal effects measured for any individual variant.
DNA diagnostics and pharmacogenetics in clinical trials
The use of genomic tools provided by the Human Genome Proj-
ect offers the opportunity to identify individuals at risk, classify 
subtypes of the disease, choose therapy based on more accurate 
diagnosis (82), more precisely delineate the environmental factors 
that contribute to the onset and progression of the disease and its 
complications, and monitor responses to therapy (83, 84). Recently, 
genetic information was applied to clinical diabetes management 
in a randomized crossover trial of gliclazide, an agent affecting 
insulin secretion, and metformin, an agent that enhances insulin 
action. Compared with patients with typical T2D, patients with 
diabetes caused by a particular MODY mutation in TCF1 (85) had 
a 4- to 5-fold greater response to gliclazide than to metformin. 
Another example was the recent finding of heterozygous mutations 
Table 1
Some known genes associated or linked with diabetes by replication in at least 2 studiesA
Type Gene Gene name Function SNP or allele or locus or marker Refs.
MODY 1 HNF4A Hepatocyte nuclear factor 4 α Transcription factor Mutations in 13 families 90, 91
MODY 2 GCK Glucokinase Glucose metabolism 130 different mutations described 92, 93
MODY 3 TCF1 Hepatocyte nuclear factor 1α Transcription factor 120 different mutations described  93, 94
    in all racial ethnic backgrounds
MODY 4 IPF1 Insulin promoter factor 1 Transcription factor Rare mutations; 1 family described 95
MODY 5 TCF2 Hepatocyte nuclear factor 1β Transcription factor Rare mutations 96, 97
MODY 6 NEUROD1 Neurogenic differentiation 1 Transcription factor Mutations described in 2 families  98
    with autosomal dominant form
T1D HLA Human leukocyte antigen Immune system regulation Variants in multiple genes 99, 100
T1D INS Insulin Involved in numerous aspects VNTR 99, 101
    of metabolism
T1D CTLA4 Cytoxic T-lymphocyte–associated protein 4 Immune system regulation T17A 102, 103
T1D PTPN22 Protein tyrosine phosphate,  Immune system regulation SNP C1858T 61, 104
  non-receptor type 22
T2D ABCC8 ATP-binding cassette,  Regulator of potassium channels  SNPs in various exons 105, 106
  subfamily C; sulfonylurea receptor and insulin release 
T2D CAPN10 Calpain 10 Protease Various intronic SNP haplotypes 70, 107
T2D GCGR Glucagon receptor Controls hepatic glucose production G40S 108, 109
    and insulin secretion
T2D GCK Glucokinase Glucose metabolism Microsatellite in 3′ end of gene 110, 111
T2D KCNJ11 Potassium inwardly-rectifying  Regulation of insulin secretion E23K 112, 113
  channel, subfamily J, member 11
T2D PPARG Peroxisome proliferator-activated  Transcription factor P12A 114, 115
  receptor γ
T2D HNF4A Hepatocyte nuclear factor 4 α Transcription factor P2 promoter SNPs 73, 74
T2D SLC2A1 Glut 1 Glucose transporter XbaI(–) restriction site 116, 117
Awith the exception of MODY 4 and MODY 6.
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in the ATP-sensitive K+ channel subunit of the Kir6.2 gene in 7 of 
11 patients with neonatal diabetes (86). This gene plays a critical 
role in glucose-stimulated insulin secretion. Remarkably, several 
patients who previously required insulin injections were taken off 
insulin and treated with oral medication, which again illustrates 
the efficacy of pharmacogenetics for treatment of some diabetics.
A large number of clinical trials for both T1D and T2D are cur-
rently being conducted. The Type 1 Diabetes Genetics Consor-
tium (T1DGC; http://www.t1dgc.org) will organize international 
efforts to identify genes that determine an individual’s risk of T1D 
through the identification of 2,500 new families with 2 or more 
affected siblings. To explore approaches to treatment of T2D in 
youth, the TODAY (Treatment Options for Type 2 Diabetes in Ado-
lescents and Youth; http://www.TODAYstudy.org) study will enroll 
750 children and teenagers that have recently been diagnosed with 
T2D. Participants will be assigned to groups for treatment aimed 
at weight reduction and increasing physical activity. The Look 
AHEAD (Action for Health in Diabetes) trial is a multicenter, 
randomized clinical trial that will examine the consequences of a 
lifestyle intervention designed to achieve and maintain weight loss 
over the long term through decreased caloric intake and increased 
exercise in 5,000 obese patients with T2D. The National Heart, 
Lung, and Blood Institute–led Action to Control Cardiovascular 
Risk in Diabetes (ACCORD) trial is designed to test the effects of 
glycemia and blood pressure control on major CVD events and 
the use of fibrate treatment to increase HDL cholesterol and lower 
triglycerides (http://www.accordtrial.org/public/index.cfm). The 
Bypass Angioplasty Revascularization Investigation 2 Diabetes 
(BARI 2D) trial (http://www.bari2d.org) addresses questions about 
therapy in adults with T2D and stable CAD who might be candi-
dates for revascularization. These studies represent ideal opportu-
nities to incorporate DNA diagnostic testing and assessment of 
variable responses to therapeutic interventions.
Large prospective cohort study for the effects of genes 
and environment on diabetes
While case-control studies have much to offer for the assessment of 
the interactions between genes and environmental factors, Francis 
Collins noted that clinically diagnosed cases may represent only the 
more severely affected individuals with the disease and highlighted 
the difficulties of selecting an unbiased control group (87). To more 
accurately quantify genetic contribution and population-wide risk, 
he proposed prospective, population-based cohort studies (88). In a 
case-control study, there would be no samples available from cases 
prior to the onset of disease to search for predictive markers. A pro-
spective study of 200,000 people would likely yield more than 5,000 
cases of diabetes, based on current prevalence, in addition to numer-
ous other features of the metabolic syndrome such as obesity, hyper-
insulinism, dyslipidemia, hypertension, and CVD. This population, 
if also studied with high-throughput, low-cost genotyping, could 
represent a major resource for physician-scientists to accelerate the 
incorporation of genetics into clinical medicine.
Unanswered questions and future opportunities
Many of the questions raised here cannot yet be answered. Will 
genome-wide association studies work in a way that genome-wide 
linkage mapping studies did not? Will the identification of more 
homogeneous subsets of patients be the key to making any real 
headway in either association or linkage mapping studies? Are non-
genetic risk factors largely uniform, or are they perhaps as variable 
as genetic risk factors? Will we really get improvement in under-
standing with a “better” version of more of the same, or do we need 
to move to something qualitatively different? Genomic technology 
is advancing rapidly, and larger, higher-powered studies will soon 
be possible — these studies should allow us to address these ques-
tions. The challenge now is for clinical scientists to provide well-
characterized populations with carefully recorded phenotypic and 
environmental data. This challenge will extend to the acquisition 
of new organizational skills to collate these data from many centers 
and provide integration with the large volume of genetic data soon 
to be generated (89). The opportunities are great for future diabetes 
genetic epidemiology research to provide clinically useful informa-
tion, the most vital goal of the Human Genome Project.
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